The Future of the Treatment of TNBC
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses future treatment options for triple-negative breast cancer (TNBC).
- BRCA-like or basal-like breast cancer that is triple-negative is particularly aggressive. Platinums may be more effective in this space.
- Many pharmaceutical companies are not looking at PARP inhibitors in large studies because of the results of 1 negative trial.
- Many TNBCs have downregulation of BRCA proteins where inhibiting PARP may be particularly effective.
- Some studies are also looking at antibodies and antibody-directed therapies to inhibit the NOTCH pathway.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
